Acasă › Limfom Burkitt › Georgia › Atlanta
Studii clinice pentru Limfom Burkitt în Atlanta, GA
12 studii pentru Limfom Burkitt caută participanți în și în jurul orașului Atlanta (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
În curs de recrutareFaza 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
În curs de recrutareFaza 3
- Emory University Hospital/Winship Cancer Institute, Atlanta
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
În curs de recrutareStudiu observațional
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
În curs de recrutareFaza 2
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
În curs de recrutareFaza 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
În curs de recrutareFaza 1
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
În curs de recrutareFaza 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
În curs de recrutareFaza 3
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
În curs de recrutareFaza 1/2
- Research Site, Atlanta
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
În curs de recrutareFaza 2
- Children's Healthcare of Atlanta at Egleston, Atlanta
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
În curs de recrutareFaza 1
- Winship Cancer Institute, Emory University, Atlanta
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
În curs de recrutareFaza 2
- Children's Healthcare of Atlanta, Atlanta
Studii pentru Limfom Burkitt în alte orașe
- Houston, TX21 studii
- Philadelphia, PA16 studii
- Milwaukee, WI16 studii
- Chicago, IL15 studii
- Cincinnati, OH13 studii
- New York City, NY13 studii
- Aurora, CO11 studii
- Seattle, WA11 studii
- Durham, NC10 studii
- Boston, MA10 studii
- Kansas City, MO10 studii
- Los Angeles, CA10 studii
Alte studii în Atlanta
- Cancer (toate tipurile)49 studii
- Cancer pulmonar cu celule non-pătrate47 studii
- Mielom multiplu42 studii
- Cancer de sân41 studii
- Cancer de prostată33 studii
- Leucemie mieloasă acută31 studii
- Cancer ovarian29 studii
- Cancer colorectal29 studii
- Cancer pulmonar29 studii
- Cancer metastatic28 studii
- Tulburare depresivă majoră25 studii
- Insuficiență cardiacă25 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.